Company Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.
Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers.
The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy.
Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| IPO Date | Oct 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Martin A. Lehr |
Contact Details
Address: 2001 Market Street Philadelphia, Pennsylvania United States | |
| Website | https://www.contexttherapeutics.com |
Stock Details
| Ticker Symbol | CNTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842952 |
| CUSIP Number | 21077P108 |
| ISIN Number | US21077P1084 |
| Employer ID | 86-3738787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director |
| Alex C. Levit Esq. | Chief Legal Officer & Corporate Secretary |
| Jennifer Minai-Azary | Chief Financial Officer & Treasurer |
| Christopher Beck M.B.A. | Senior Vice President of Operations |
| Dr. Claudio Dansky Ullmann M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 3 | Filing |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 08, 2025 | SCHEDULE 13G | Filing |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 02, 2024 | 8-K | Current Report |
| Dec 02, 2024 | 424B5 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |